Navigation Links
FDA Approves Merz Pharmaceuticals' Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
Date:8/2/2010

, a wholly owned U.S. subsidiary of the Merz Group of Companies and was established in 1995 to develop and commercialize products for the Merz Group.  Areas of therapeutic focus include Neurology, Dermatology, and Podiatry along with the #1 non-prescription product for scars, Mederma®, and Mederma® Stretch Marks Therapy.

With a 102 year heritage, Merz (KGaA) is known worldwide for its development of original compounds and formulations for medical professionals and consumers in 90 countries. Globally, Merz is a leader in the development of pharmaceuticals for the treatment of neurological and psychological disorders as well as for aesthetic medicine. Global research is concentrated in fields that have a strong need for therapeutic innovation such as Alzheimer's disease, Parkinson's disease, tinnitus, chronic pain conditions, addictions, and neuromuscular disturbances.


'/>"/>
SOURCE Merz Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 Revenue and earnings above the ... and development In the past 2013/14 fiscal year ... percent to EUR 4.287 billion (last year: EUR 4.190 billion) ... to EUR 360 million. "Overall, 2013/14 was a successful fiscal ... , President and CEO of Carl Zeiss AG. "Thanks to ...
(Date:12/17/2014)... , Dec. 17, 2014  Beamz Interactive, Inc. ... music products, today announced that it has signed ... manufacturer and supplier of innovative prosthetic, orthotic and ... part of the agreement, RSL Steeper will promote ... specifically configured for use within UK residential care ...
(Date:12/17/2014)... , Dec. 17, 2014  RXi Pharmaceuticals Corporation ... focused on discovering, developing and commercializing innovative therapies ... today announced completion of enrollment in its first Phase ... 3-month observations confirmed the 1-month findings that were ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... PALO ALTO, Calif., May 5, 2011 Varian Medical ... its ARIA® for radiation oncology information system has received ... This means physicians using the ARIA system to manage ... electronically with pharmacies connected to the Surescripts network. ...
... May 5, 2011 Dyadic International, Inc. ("Dyadic") ... on the discovery, development, manufacture and sale of ... enzyme and biopharmaceutical industries, today announced financial results ... financial information contained in this press release should ...
Cached Medicine Technology:The ARIA® for Radiation Oncology Information System from Varian Medical Systems Now Certified by Surescripts® for E-Prescribing 2The ARIA® for Radiation Oncology Information System from Varian Medical Systems Now Certified by Surescripts® for E-Prescribing 3Dyadic International Reports 2011 First Quarter Financial Results 2Dyadic International Reports 2011 First Quarter Financial Results 3Dyadic International Reports 2011 First Quarter Financial Results 4Dyadic International Reports 2011 First Quarter Financial Results 5
(Date:12/19/2014)... -- A new study suggests a possible link between ... and night sweats -- and higher rates of hip ... during menopause, affecting about 60 percent of women. The ... since they then face a higher risk of weakened ... exhibit moderate or severe menopausal symptoms are more likely ...
(Date:12/19/2014)... Dotinga HealthDay Reporter ... including ibuprofen, might slightly reduce your risk of developing ... of ibuprofen (Advil, Motrin) and naproxen (Aleve) appear to ... 15 percent, the researchers concluded after reviewing nine prior ... sun exposure. These painkillers "have potential ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. 18, ... leg for at least 20 seconds you may be at ... on one leg may indicate that small strokes or tiny ... serious strokes is high, the investigators reported online Dec. 18 ... while standing on one leg, as well as problems walking, ...
(Date:12/17/2014)... Mass. (PRWEB) December 17, 2014 ... of Osteopathic Medicine (ACOM), which welcomed its inaugural ... Desktop Infrastructure (VDI) to seamlessly support bring your ... – and teaching – experience. The solution, comprised ... NetScaler , Dell server and storage infrastructure ...
(Date:12/17/2014)... December 17, 2014 A group of 127 ... Longevity, today, in reaction to a recent statement by the ... brain training and derogated the efficacy of all brain exercises. ... with the parts of the center’s statement critical of brain ... center had also overstated its case, in a document it ...
Breaking Medicine News(10 mins):Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4
... (SAN FRANCISCO, December 6, 2008) Four studies highlighting ... sickle cell disease will be presented today at the ... in San Francisco, CA. , Results from a ... improve endothelial dysfunction, a malfunction in the inner lining ...
... The use of dexamethasone early in the treatment of children ... cancer, may help reduce the risk of relapse according to ... December 6, at 2:00 p.m., during the 50th Annual Meeting ... Additional research will be featured at the press conference that ...
... 2008) A study assessing the quality of care for ... settings will be presented at a press conference on Saturday, ... of the American Society of Hematology in San Francisco, CA. ... risk in children with sickle cell disease, as well as ...
... 6, 2008) Four studies that highlight significant advances ... forms of thrombocytopenia, a group of bleeding disorders characterized ... will be presented in a press conference on Saturday, ... Meeting of the American Society of Hematology in San ...
... a call from a biotech lab in Korea. He was told ... clone of a pet dog, his beloved family mutt, Missy. Now ... healthy puppy living the good life in Mill Valley, California. “Not ... coat feels the same, and she has some of the same ...
... for Leadership on Right to Health , ... Boston (Vocus) December 5, ... community members and experts join for a landmark town meeting titled ,HIV/AIDS ... event, which commemorates World AIDS Day and the 60th anniversary of the ...
Cached Medicine News:Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 2Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 3Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 4Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 5Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 6Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 7Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 2Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 3Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 4Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 5Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 6Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 7Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 8Health News:Studies examine quality of care for hospitalized sickle cell disease patients 2Health News:Studies examine quality of care for hospitalized sickle cell disease patients 3Health News:Studies examine quality of care for hospitalized sickle cell disease patients 4Health News:Studies examine quality of care for hospitalized sickle cell disease patients 5Health News:Studies examine quality of care for hospitalized sickle cell disease patients 6Health News:Studies examine quality of care for hospitalized sickle cell disease patients 7Health News:Studies examine quality of care for hospitalized sickle cell disease patients 8Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 2Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 3Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 4Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 5Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 6Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 7Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 8Health News:Cloned Canine Celebrates Her 1st Birthday 2Health News:Community Unites for Physicians for Human Rights Town Meeting on Global AIDS and Human Rights on December 8 2Health News:Community Unites for Physicians for Human Rights Town Meeting on Global AIDS and Human Rights on December 8 3Health News:Community Unites for Physicians for Human Rights Town Meeting on Global AIDS and Human Rights on December 8 4Health News:Community Unites for Physicians for Human Rights Town Meeting on Global AIDS and Human Rights on December 8 5Health News:Community Unites for Physicians for Human Rights Town Meeting on Global AIDS and Human Rights on December 8 6
... Portex® medication nebulizers offer a spill-proof ... up to a 45° angle. All medical ... ,A wide variety of configurations are available., ... latex-free. , ,Portex® medication nebulizers feature ...
... procedural kit contains everything the health care ... test quickly and efficiently: 7 nebulizers, T-piece ... syringe and needle., ,Shipped 5 kits ... European Community., ,Intended Use: AsthmaKit is ...
... be held at angles up to 45° without ... spill column, finger grooves for a non-slip gripping ... feet of regular oxygen tubing. The large ... and sustain optimum mist concentration at every setting. ...
Aerosolized Medication Device for Infants. An alternative to aerosol blow-by., ,The PediNeb™ was designed to enhance the delivery of aerosolized medication, while reducing the apprehension enc...
Medicine Products: